Overview
CalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-ago
Positive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026
Outlook
Company expects cash position to fund operations into 2H 2026
CalciMedica expects pivotal trial design for AP finalized in 1H 2026
Data from Phase 2 KOURAGE trial expected in 1H 2026
Result Drivers
COSTS - R&D costs rose to $3.9 mln from $3.6 mln, while G&A expenses dropped to $1.8 mln from $2.2 mln
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$7.80 mln
Q3 Basic EPS
-$0.52
Q3 Income From Operations
-$5.62 mln
Q3 Operating Expenses
$5.62 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CalciMedica Inc is $15.50, about 79.3% above its November 11 closing price of $3.21
Press Release: ID:nPn5W9Ry8a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
